[Form 4] ResMed Inc. Insider Trading Activity

Rhea-AI Filing Summary

ResMed Inc. Chief Executive Officer Michael J. Farrell reported the vesting and receipt of performance-based restricted stock units. On 08/15/2025, 12,289 shares of ResMed common stock were acquired at a $0 price because they were earned under a performance-based restricted stock unit award granted 11/20/2024 after the compensation committee certified that performance metrics were met. After the transaction, Farrell beneficially owned 467,792 shares directly and held an indirect interest in 2,090 shares through the Lisette and Michael Farrell Family Trust. The award vests one-third each year on the grant anniversary.

Positive

• Performance metrics were met, triggering the vesting and delivery of 12,289 performance-based restricted stock units.
• Insider alignment increased as CEO Michael J. Farrell's direct beneficial ownership rose to 467,792 shares.
• No cash paid for the vested units, reflecting fulfillment of long-term incentive conditions rather than a market purchase.

Negative

• None.

Insights

Financial Analyst

TL;DR: CEO received vested performance RSUs, increasing direct holdings modestly; the award reflects achieved performance metrics.

This Form 4 discloses a routine vesting of performance-based restricted stock units for the CEO, resulting in a non-cash acquisition of 12,289 shares. The transaction conveys that the board’s compensation committee certified attainment of whatever performance targets governed the award, triggering payout. The change increases direct ownership to 467,792 shares, a potentially relevant datapoint for insider alignment but not a material capital event on its own.

Corporate Governance Expert

TL;DR: Vesting of performance RSUs indicates governance-approved achievement of targets; disclosure is standard and transparent.

The filing documents a compensation-driven equity issuance that vested after certification of pre-set metrics. The award’s one-third annual vesting schedule and the certification process are disclosed, aligning with common governance practices. There is no cash consideration and no sale reported, so governance implications relate to incentive design rather than liquidity or related-party transactions.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Farrell Michael J.

(Last) (First) (Middle)

RESMED INC.

9001 SPECTRUM CENTER BLVD

(Street)

SAN DIEGO CA 92123

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
RESMED INC [ RMD ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Executive Officer

3. Date of Earliest Transaction (Month/Day/Year)
08/15/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
ResMed Common Stock	08/15/2025		A(1)		12,289	A	$0	467,792	D
ResMed Common Stock								2,090	I	Lisette and Michael Farrell Family Trust

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents performance-based restricted stock units granted on November 20, 2024. The shares were earned on August 15, 2025, when the compensation committee certified that the performance metrics were met. Stock units vest1/3 each year on the anniversary of the grant.

	Michael J. Farrell, Chief Executive Officer	08/19/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did RMD CEO Michael J. Farrell acquire according to the Form 4?

He acquired 12,289 shares of ResMed common stock on 08/15/2025 through vesting of performance-based restricted stock units.

Why were the 12,289 shares issued at a $0 price on the Form 4?

They were earned under performance-based restricted stock units granted on 11/20/2024 and vested when the compensation committee certified performance metrics were met.

How many ResMed shares does Michael J. Farrell beneficially own after this transaction?

He beneficially owns 467,792 shares directly and has an indirect interest in 2,090 shares via the Lisette and Michael Farrell Family Trust.

When do the remaining RSU tranches vest?

The award vests one-third each year on the anniversary of the grant (grant date 11/20/2024), per the Form 4 explanation.